Study analysis · The lancet. Gastroenterology & hepatology · 2020
This weekly shot slashed liver fat by 5.2%—but 4 patients had 6 serious health crises.
A weekly injection reduced fat in the liver of people with diabetes, without making their blood sugar or weight worse.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave one group a new medicine and another group a fake pill, then measured if the medicine reduced fat in the liver. Because they randomly assigned people and didn't tell anyone who got what, we can be pretty sure the medicine caused the change — not just luck or other factors.
What’s the bottom line?
Scientists tested a new weekly shot that blocks a liver enzyme that makes fat. They gave it to people with type 2 diabetes and fatty liver to see if it helped.
How strong is this study?
This study was well-designed because it used random assignment and kept everyone blind to who got the real medicine, which helps avoid bias. But it only had 44 people and didn't follow them long, so we can't be totally sure it works for everyone or for a long time.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
80 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=44)+4.0/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is a randomized, double-blind, placebo-controlled trial with a statistically significant primary outcome, which allows for causal inference. However, the small sample size (n=44) and lack of full-text access limit confidence in long-term or subgroup effects.
Major COI
Major conflicts that significantly reduce study credibility
The study was fully funded by Ionis Pharmaceuticals, the developer of the investigational drug IONIS-DGAT2Rx, and while funder involvement in design and analysis is not explicitly stated, the lack of independent oversight safeguards raises significant conflict concerns.
Funders
Conflict Details
Ionis Pharmaceuticals: Study funded by Ionis Pharmaceuticals, developer of the investigational drug IONIS-DGAT2Rx.
Although the study was double-blind and included masked central readers, there is no mention of an independent data monitoring committee, statistical analysis plan overseen by an independent party, or publication governance safeguards. The sole funder is the drug developer, creating a high risk of bias despite methodological rigor.
Key takeaways
- 01
The shot reduced liver fat by 5.2%, while the placebo group only lost 0.6%.
- 02
The difference was 4.2% and statistically significant.
- 03
A 4.2% drop in liver fat is meaningful — it’s like reducing a large slice of fat in the liver, which may lower risk of liver damage.
Practical takeaways
If you have type 2 diabetes and fatty liver, ask your doctor if you’re eligible for clinical trials of DGAT2 inhibitors like IONIS-DGAT2Rx.
This drug is still experimental and not approved for public use. The study was small and short-term.
low confidenceWhy this study matters
Liver Fat Plummets With One Shot
After 13 weeks of once-weekly injections, participants taking IONIS-DGAT2Rx saw their liver fat drop by 5.2% on average, while the placebo group only dropped 0.6%. The difference of 4.2% was statistically significant (p=0.026).
Fatty liver is super common in people with type 2 diabetes, and this is one of the first drugs to show a clear, measurable reduction without worsening other health markers.
No Weight Gain, No Blood Sugar Spike
Despite reducing liver fat, the drug didn’t increase blood glucose, body weight, aminotransferases, or cause GI side effects compared to placebo.
Most liver fat treatments either cause weight gain or worsen insulin resistance—this one didn’t, which is rare and promising.
Six Serious Events—But Not the Drug’s Fault?
Four patients in the drug group had six serious adverse events—including cardiac arrest, stroke, and pancreatitis—but researchers said none were related to the drug.
In a tiny group of 29 people, 4 had life-threatening events—yet the study dismisses any link. That’s a red flag for some experts.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a new weekly shot that blocks a liver enzyme that makes fat. They gave it to people with type 2 diabetes and fatty liver to see if it helped.
Research results
The shot reduced liver fat by 5.2%, while the placebo group only lost 0.6%. The difference was 4.2% and statistically significant.
What this means - more context
A 4.2% drop in liver fat is meaningful — it’s like reducing a large slice of fat in the liver, which may lower risk of liver damage.
This study evaluates whether IONIS-DGAT2Rx, an antisense oligonucleotide inhibitor of DGAT2, reduces liver fat in adults with type 2 diabetes and NAFLD.
In a 13-week randomized, double-blind, placebo-controlled trial, once-weekly subcutaneous IONIS-DGAT2Rx (250 mg) reduced liver fat by 5.2% compared to 0.6% with placebo (treatment difference: -4.2%, p=0.026). No significant increases in aminotransferases, glucose, weight, or GI side effects were observed. Six serious adverse events occurred in the drug group, all deemed unrelated to the drug.
Methods Used
Double-blind, randomized, placebo-controlled phase 2 trial with 44 participants (29 drug, 15 placebo) aged 18–75 with type 2 diabetes, BMI 27–39 kg/m², HbA1c 7.3–9.5%, and liver fat ≥10%. Treatment: once-weekly subcutaneous injection for 13 weeks. Primary endpoint: change in liver fat percentage measured by MRI-estimated proton density fat fraction in the per-protocol population.
Main Finding
IONIS-DGAT2Rx reduced liver fat by 5.2% (SD 5.4) versus 0.6% (SD 6.1) with placebo, a statistically significant treatment difference of -4.2% (95% CI -7.8 to -0.5, p=0.026). No significant changes in serum aminotransferases, plasma glucose, body weight, or gastrointestinal side effects were observed compared to placebo.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Small sample size (n=44)
- •Serious adverse events in drug group (n=6) despite being deemed unrelated
Practical Takeaways
If you have type 2 diabetes and fatty liver, ask your doctor if you’re eligible for clinical trials of DGAT2 inhibitors like IONIS-DGAT2Rx.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave one group a new medicine and another group a fake pill, then measured if the medicine reduced fat in the liver. Because they randomly assigned people and didn't tell anyone who got what, we can be pretty sure the medicine caused the change — not just luck or other factors.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Objective primary endpoint (MRI-quantified liver fat)
- Clear inclusion/exclusion criteria
Weaknesses
- Small sample size (n=44)
- Short duration (13-week treatment, 13-week follow-up)
- Exclusion of patients with advanced NASH or severe comorbidities
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a new weekly shot that blocks a liver enzyme that makes fat. They gave it to people with type 2 diabetes and fatty liver to see if it helped.
Research results
The shot reduced liver fat by 5.2%, while the placebo group only lost 0.6%. The difference was 4.2% and statistically significant.
What this means - more context
A 4.2% drop in liver fat is meaningful — it’s like reducing a large slice of fat in the liver, which may lower risk of liver damage.
This study evaluates whether IONIS-DGAT2Rx, an antisense oligonucleotide inhibitor of DGAT2, reduces liver fat in adults with type 2 diabetes and NAFLD.
In a 13-week randomized, double-blind, placebo-controlled trial, once-weekly subcutaneous IONIS-DGAT2Rx (250 mg) reduced liver fat by 5.2% compared to 0.6% with placebo (treatment difference: -4.2%, p=0.026). No significant increases in aminotransferases, glucose, weight, or GI side effects were observed. Six serious adverse events occurred in the drug group, all deemed unrelated to the drug.
Methods Used
Double-blind, randomized, placebo-controlled phase 2 trial with 44 participants (29 drug, 15 placebo) aged 18–75 with type 2 diabetes, BMI 27–39 kg/m², HbA1c 7.3–9.5%, and liver fat ≥10%. Treatment: once-weekly subcutaneous injection for 13 weeks. Primary endpoint: change in liver fat percentage measured by MRI-estimated proton density fat fraction in the per-protocol population.
Main Finding
IONIS-DGAT2Rx reduced liver fat by 5.2% (SD 5.4) versus 0.6% (SD 6.1) with placebo, a statistically significant treatment difference of -4.2% (95% CI -7.8 to -0.5, p=0.026). No significant changes in serum aminotransferases, plasma glucose, body weight, or gastrointestinal side effects were observed compared to placebo.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Small sample size (n=44)
- •Serious adverse events in drug group (n=6) despite being deemed unrelated
Practical Takeaways
If you have type 2 diabetes and fatty liver, ask your doctor if you’re eligible for clinical trials of DGAT2 inhibitors like IONIS-DGAT2Rx.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave one group a new medicine and another group a fake pill, then measured if the medicine reduced fat in the liver. Because they randomly assigned people and didn't tell anyone who got what, we can be pretty sure the medicine caused the change — not just luck or other factors.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Objective primary endpoint (MRI-quantified liver fat)
- Clear inclusion/exclusion criteria
Weaknesses
- Small sample size (n=44)
- Short duration (13-week treatment, 13-week follow-up)
- Exclusion of patients with advanced NASH or severe comorbidities
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was well-designed because it used random assignment and kept everyone blind to who got the real medicine, which helps avoid bias. But it only had 44 people and didn't follow them long, so we can't be totally sure it works for everyone or for a long time.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
80 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=44)+4.0/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is a randomized, double-blind, placebo-controlled trial with a statistically significant primary outcome, which allows for causal inference. However, the small sample size (n=44) and lack of full-text access limit confidence in long-term or subgroup effects.
Major COI
Major conflicts that significantly reduce study credibility
The study was fully funded by Ionis Pharmaceuticals, the developer of the investigational drug IONIS-DGAT2Rx, and while funder involvement in design and analysis is not explicitly stated, the lack of independent oversight safeguards raises significant conflict concerns.
Funders
Conflict Details
Ionis Pharmaceuticals: Study funded by Ionis Pharmaceuticals, developer of the investigational drug IONIS-DGAT2Rx.
Although the study was double-blind and included masked central readers, there is no mention of an independent data monitoring committee, statistical analysis plan overseen by an independent party, or publication governance safeguards. The sole funder is the drug developer, creating a high risk of bias despite methodological rigor.